In this online CME self-learning activity:
Alpha 1-antitrypsin deficiency (AATD), characterized by low serum levels of the serine protease inhibitor alpha-1 antitrypsin (AAT), is a genetic disorder resulting in destruction of lung structures. Reduced levels of AAT result in overactivity of neutrophil elastase, which destroys connective tissue within the lung and causes degradation of alveoli, reduced pulmonary elastic recoil, and airflow. Breakdown of the alveoli eventually manifest as emphysema or other forms of chronic lung disease, including chronic obstructive lung disease (COPD). Other complications associated with AATD include liver disease, panniculitis, and vasculitis. The most common cause of death in patients with severe AATD is respiratory failure, which accounts for 45 to 72% of deaths. Smoking, occupational hazards such as firefighting, and high levels of cumulative exposure to pollution accelerate the rate of lung function decline in people with AATD. AATD is estimated to affect one out of every 2,000 to 5,000 individuals, mainly of North European or Iberian ancestry, with a global prevalence of over 3.4 million affected individuals.
The following healthcare professionals: pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.
Commercial Support Disclosure: This activity is supported by an educational grant from Takeda and CSL Behring.
Learners may participate in this activity free of charge.
Release Date: July 26, 2020 -- Expiration Date: July 26, 2022
Faculty: Igor Barjaktarevic, MD
Faculty introduction, disclosures
Introduction content: review of AATD pathophysiology, diagnosis
Treatment of AATD
Barriers to care
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201806113
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Igor Barjaktarevic, MD, PhD, Assistant Professor, Medical Director of COPD program, Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, has received financial support (consulting and/or research) from PCORI, COPD Foundation, AMGEN, GE Healthcare, Theravance, Mylan, Astra Zeneca, Boehringer, GSK, Verona Pharma, Theravance, Grifols, CSL Behring, Shire, Adverum, Vertex, Kamada, Arrowhead, and Mereo
Disclosure of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.